| Literature DB >> 11896097 |
M Margaret Kemeny1, Sudeshna Adak, Bruce Gray, John S Macdonald, Thomas Smith, Stuart Lipsitz, Elin R Sigurdson, Peter J O'Dwyer, Al B Benson.
Abstract
PURPOSE: Despite technical improvements that have minimized the morbidity and mortality of hepatic surgery, the long-term outcome of resection of hepatic metastases of colorectal cancer remains poor, with the majority of patients experiencing treatment failure in the liver. Because arterial chemotherapy regimens targeted to the liver have demonstrated high response rates, an intergroup trial of adjuvant therapy for patients undergoing hepatic resection of liver metastases from colorectal cancer was initiated. PATIENTS AND METHODS: Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients). After exclusion of patients identified as ineligible for the planned treatment at the time of surgery, there were 45 control patients and 30 on the chemotherapy arm. The study was powered to evaluate improvement in time to recurrence and hepatic disease-free survival, not overall survival.Entities:
Mesh:
Substances:
Year: 2002 PMID: 11896097 DOI: 10.1200/JCO.2002.20.6.1499
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544